Clinical trials
Low Grade Serous Ovarian Cancer clinical trials
Below are recruiting low grade serous ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06404671Recruiting
Timing of surgery after chemo for advanced ovarian cancer
This trial tests whether waiting longer between chemotherapy and surgery affects outcomes for advanced ovarian cancer. It is for women who have had three cycles of chemo and whose disease can be removed surgically.
AlexandriaAges 18–75 - NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT04315233RecruitingPhase 1
Testing two drugs for hard-to-treat triple-negative breast and ovarian cancer
This Phase 1 trial tests ribociclib plus belinostat in people with metastatic triple-negative breast cancer or recurrent ovarian cancer. It also looks at your tumor’s genetics (from a fresh biopsy) to see who might respond better.
Salt Lake City, UtahAges 18 years+ - NCT04606914RecruitingPhase 2
Carboplatin plus mirvetuximab for advanced ovarian cancer after chemo
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Birmingham, AlabamaAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Anchorage, AlaskaAges 18 years+ - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Mobile, AlabamaAges 18–99 - NCT05952453RecruitingPhase 2
New ovarian cancer treatment with chemo plus maintenance medicines
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Teaneck, New JerseyAges 18 years+ - NCT04361370Enrolling by invitationPhase 2
Olaparib plus pembrolizumab and bevacizumab after ovarian cancer
This trial tests whether adding olaparib, pembrolizumab, and bevacizumab as ongoing (“maintenance”) treatment can help control platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer that has responded to prior chemotherapy. It focuses on people whose tumors do NOT have BRCA1/2 gene mutations.
SeoulAges 20 years+ - NCT07489287RecruitingPhase 1
GB-5267 for platinum-resistant ovarian, peritoneal, or fallopian tube cancer
This trial tests a new cell therapy (GB-5267) for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer. It requires multiple tumor biopsies and aims to see if the treatment can help when standard chemo stops working.
Buffalo, New YorkAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT06476184RecruitingPhase 3
Adjusted chemo dosing for hard-to-treat ovarian cancer
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
AngersAges 18 years+ - NCT05607329Recruiting
Surgery plus chemo versus chemo alone for ovarian cancer relapse
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hangzhou, ZhejiangAges 18–70 - NCT06836219Recruiting
Study of treatment outcomes based on HRD status in advanced ovarian cancer
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
Bari, BAAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Orlando, FloridaAges 18 years+ - NCT06331130Recruiting
Mesenteric involvement in ovarian cancer trial
This study is looking at how ovarian cancer affects the mesentery (the tissue that holds your intestines in place) in women with advanced ovarian cancer. It helps doctors understand the disease better and may lead to improved treatments.
RomaAges 18 years+ - NCT07667751RecruitingPhase 2
Study of Ipalotinib with Sunitinib and Olaparib before surgery for advanced ovarian cancer
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
HefeiAges 18–75 - NCT07286266RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
Randwick, New South WalesAges 18 years+ - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT03275194RecruitingPhase 2
HIPEC during interval surgery for advanced ovarian cancer
This trial looks at whether a heated chemotherapy treatment given in the abdomen during a planned second surgery (HIPEC) can improve outcomes for certain advanced ovarian cancers. It is for people who have already had initial chemotherapy and partially responded, with enough health to safely undergo surgery.
Mexico CityAges 18–70 - NCT06412120RecruitingPhase 4
Niraparib safety and metabolism study in Black women
This trial tests a new maintenance therapy called niraparib for Black women who have finished initial treatment for advanced ovarian cancer and are in remission or partial response. It aims to see if the drug is safe and how your body processes it.
Fort Lauderdale, FloridaAges 18 years+ - NCT06614790Recruiting
Niraparib maintenance for advanced ovarian cancer
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
BialystokAges 18 years+ - NCT07169396Recruiting
Genetic study for ovarian cancer treatments
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
Reggio EmiliaAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+
Hear when a new Low Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for low grade serous ovarian cancer?
- Yes. Clin2 currently lists 72 recruiting low grade serous ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a low grade serous ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a low grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.